158 related articles for article (PubMed ID: 21047561)
1. Reduced-intensity conditioning followed by related allografts in hematologic malignancies: long-term outcomes most successful in indolent and aggressive non-Hodgkin lymphomas.
Warlick ED; Tomblyn M; Cao Q; Defor T; Blazar BR; Macmillan M; Verneris M; Wagner J; Dusenbery K; Aurora M; Bachanova V; Brunstein C; Burns L; Cooley S; Kaufman D; Majhail NS; McClune B; McGlave P; Miller J; Oran B; Slungaard A; Vercellotti G; Weisdorf DJ
Biol Blood Marrow Transplant; 2011 Jul; 17(7):1025-32. PubMed ID: 21047561
[TBL] [Abstract][Full Text] [Related]
2. Reduced-Intensity Compared to Nonmyeloablative Conditioning in Patients with Non-Hodgkin Lymphoma Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.
Nath K; Peterson K; Brown S; Devlin S; Rodriguez N; Barker J; Giralt S; Gyurkocza B; Jakubowski A; Papadopoulos E; Ponce D; Scordo M; Shah G; Perales MA; Sauter C; Lin A; Dahi PB
Transplant Cell Ther; 2024 Jan; 30(1):81-92. PubMed ID: 37788792
[TBL] [Abstract][Full Text] [Related]
3. Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders.
Laport GG; Sandmaier BM; Storer BE; Scott BL; Stuart MJ; Lange T; Maris MB; Agura ED; Chauncey TR; Wong RM; Forman SJ; Petersen FB; Wade JC; Epner E; Bruno B; Bethge WA; Curtin PT; Maloney DG; Blume KG; Storb RF
Biol Blood Marrow Transplant; 2008 Feb; 14(2):246-55. PubMed ID: 18215785
[TBL] [Abstract][Full Text] [Related]
4. Effect of conditioning regimen intensity on acute myeloid leukemia outcomes after umbilical cord blood transplantation.
Oran B; Wagner JE; DeFor TE; Weisdorf DJ; Brunstein CG
Biol Blood Marrow Transplant; 2011 Sep; 17(9):1327-34. PubMed ID: 21232621
[TBL] [Abstract][Full Text] [Related]
5. 90Y-ibritumomab tiuxetan, fludarabine, busulfan and antithymocyte globulin reduced-intensity allogeneic transplant conditioning for patients with advanced and high-risk B-cell lymphomas.
Bouabdallah K; Furst S; Asselineau J; Chevalier P; Tournilhac O; Ceballos P; Vigouroux S; Tabrizi R; Doussau A; Bouabdallah R; Mohty M; Le Gouill S; Blaise D; Milpied N
Ann Oncol; 2015 Jan; 26(1):193-198. PubMed ID: 25361987
[TBL] [Abstract][Full Text] [Related]
6. Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome.
Armand P; Kim HT; Ho VT; Cutler CS; Koreth J; Antin JH; LaCasce AS; Jacobsen ED; Fisher DC; Brown JR; Canellos GP; Freedman AS; Soiffer RJ; Alyea EP
Biol Blood Marrow Transplant; 2008 Apr; 14(4):418-25. PubMed ID: 18342784
[TBL] [Abstract][Full Text] [Related]
7. Clofarabine versus fludarabine-based reduced-intensity conditioning regimen prior to allogeneic transplantation in adults with AML/MDS.
Chevallier P; Labopin M; de La Tour RP; Lioure B; Bulabois CE; Huynh A; Blaise D; Turlure P; Daguindau E; Maillard N; Yakoub-Agha I; Guillerm G; Delage J; Contentin N; Bay JO; Beckerich F; Bourhis JH; Detrait M; Vigouroux S; François S; Legrand F; Guillaume T; Mohty M;
Cancer Med; 2016 Nov; 5(11):3068-3076. PubMed ID: 27748046
[TBL] [Abstract][Full Text] [Related]
8. Long-term outcomes of patients with persistent indolent B cell malignancies undergoing nonmyeloablative allogeneic transplantation.
Cassaday RD; Storer BE; Sorror ML; Sandmaier BM; Guthrie KA; Maloney DG; Rajendran JG; Pagel JM; Flowers ME; Green DJ; Rezvani AR; Storb RF; Press OW; Gopal AK
Biol Blood Marrow Transplant; 2015 Feb; 21(2):281-7. PubMed ID: 25445025
[TBL] [Abstract][Full Text] [Related]
9. Allotransplantation for patients age ≥40 years with non-Hodgkin lymphoma: encouraging progression-free survival.
McClune BL; Ahn KW; Wang HL; Antin JH; Artz AS; Cahn JY; Deol A; Freytes CO; Hamadani M; Holmberg LA; Jagasia MH; Jakubowski AA; Kharfan-Dabaja MA; Lazarus HM; Miller AM; Olsson R; Pedersen TL; Pidala J; Pulsipher MA; Rowe JM; Saber W; van Besien KW; Waller EK; Aljurf MD; Akpek G; Bacher U; Chao NJ; Chen YB; Cooper BW; Dehn J; de Lima MJ; Hsu JW; Lewis ID; Marks DI; McGuirk J; Cairo MS; Schouten HC; Szer J; Ramanathan M; Savani BN; Seftel M; Socie G; Vij R; Warlick ED; Weisdorf DJ
Biol Blood Marrow Transplant; 2014 Jul; 20(7):960-8. PubMed ID: 24641829
[TBL] [Abstract][Full Text] [Related]
10. Allogeneic Transplantation to Treat Therapy-Related Myelodysplastic Syndrome and Acute Myelogenous Leukemia in Adults.
Metheny L; Callander NS; Hall AC; Zhang MJ; Bo-Subait K; Wang HL; Agrawal V; Al-Homsi AS; Assal A; Bacher U; Beitinjaneh A; Bejanyan N; Bhatt VR; Bredeson C; Byrne M; Cairo M; Cerny J; DeFilipp Z; Perez MAD; Freytes CO; Ganguly S; Grunwald MR; Hashmi S; Hildebrandt GC; Inamoto Y; Kanakry CG; Kharfan-Dabaja MA; Lazarus HM; Lee JW; Nathan S; Nishihori T; Olsson RF; Ringdén O; Rizzieri D; Savani BN; Savoie ML; Seo S; van der Poel M; Verdonck LF; Wagner JL; Yared JA; Hourigan CS; Kebriaei P; Litzow M; Sandmaier BM; Saber W; Weisdorf D; de Lima M
Transplant Cell Ther; 2021 Nov; 27(11):923.e1-923.e12. PubMed ID: 34428556
[TBL] [Abstract][Full Text] [Related]
11. Long-Term Follow-Up of
Puronen CE; Cassaday RD; Stevenson PA; Sandmaier BM; Flowers ME; Green DJ; Maloney DG; Storb RF; Press OW; Gopal AK
Biol Blood Marrow Transplant; 2018 Nov; 24(11):2211-2215. PubMed ID: 30454872
[TBL] [Abstract][Full Text] [Related]
12. Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning.
Kahl C; Storer BE; Sandmaier BM; Mielcarek M; Maris MB; Blume KG; Niederwieser D; Chauncey TR; Forman SJ; Agura E; Leis JF; Bruno B; Langston A; Pulsipher MA; McSweeney PA; Wade JC; Epner E; Bo Petersen F; Bethge WA; Maloney DG; Storb R
Blood; 2007 Oct; 110(7):2744-8. PubMed ID: 17595333
[TBL] [Abstract][Full Text] [Related]
13. Long-term survival with low toxicity after allogeneic transplantation for acute myeloid leukaemia and myelodysplasia using non-myeloablative conditioning without T cell depletion.
Davies JK; Taussig D; Oakervee H; Smith M; Agrawal S; Cavenagh JD; Gribben JG
Br J Haematol; 2013 Aug; 162(4):525-9. PubMed ID: 23718277
[TBL] [Abstract][Full Text] [Related]
14. Allogeneic stem cell transplantation for X-linked agammaglobulinemia using reduced intensity conditioning as a model of the reconstitution of humoral immunity.
Ikegame K; Imai K; Yamashita M; Hoshino A; Kanegane H; Morio T; Kaida K; Inoue T; Soma T; Tamaki H; Okada M; Ogawa H
J Hematol Oncol; 2016 Feb; 9():9. PubMed ID: 26873735
[TBL] [Abstract][Full Text] [Related]
15. Sequential vs myeloablative vs reduced intensity conditioning for patients with myelodysplastic syndromes with an excess of blasts at time of allogeneic haematopoietic cell transplantation: a retrospective study by the chronic malignancies working party of the EBMT.
Potter V; Gras L; Koster L; Kroger N; Sockel K; Ganser A; Finke J; Labussiere-Wallet H; Peffault de Latour R; Koc Y; Salmenniemi U; Smidstrup Friis L; Jindra P; Schroeder T; Tischer J; Arat M; Pascual Cascon M; de Wreede LC; Hayden P; Raj K; Drozd-Sokolowska J; Scheid C; McLornan DP; Robin M; Yakoub-Agha I
Bone Marrow Transplant; 2024 Feb; 59(2):224-231. PubMed ID: 37993503
[TBL] [Abstract][Full Text] [Related]
16. Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma.
Radivoyevitch T; Dean RM; Shaw BE; Brazauskas R; Tecca HR; Molenaar RJ; Battiwalla M; Savani BN; Flowers MED; Cooke KR; Hamilton BK; Kalaycio M; Maciejewski JP; Ahmed I; Akpek G; Bajel A; Buchbinder D; Cahn JY; D'Souza A; Daly A; DeFilipp Z; Ganguly S; Hamadani M; Hayashi RJ; Hematti P; Inamoto Y; Khera N; Kindwall-Keller T; Landau H; Lazarus H; Majhail NS; Marks DI; Olsson RF; Seo S; Steinberg A; William BM; Wirk B; Yared JA; Aljurf M; Abidi MH; Allewelt H; Beitinjaneh A; Cook R; Cornell RF; Fay JW; Hale G; Chakrabarty JH; Jodele S; Kasow KA; Mahindra A; Malone AK; Popat U; Rizzo JD; Schouten HC; Warwick AB; Wood WA; Sekeres MA; Litzow MR; Gale RP; Hashmi SK
Leuk Res; 2018 Nov; 74():130-136. PubMed ID: 30055822
[TBL] [Abstract][Full Text] [Related]
17. Impact of Conditioning Intensity and Genomics on Relapse After Allogeneic Transplantation for Patients With Myelodysplastic Syndrome.
Dillon LW; Gui G; Logan BR; Fei M; Ghannam J; Li Y; Licon A; Alyea EP; Bashey A; Devine SM; Fernandez HF; Giralt S; Hamadani M; Howard A; Maziarz RT; Porter DL; Warlick ED; Pasquini MC; Scott BL; Horwitz ME; Deeg HJ; Hourigan CS
JCO Precis Oncol; 2021; 5():. PubMed ID: 34036237
[TBL] [Abstract][Full Text] [Related]
18. Second solid cancers after allogeneic hematopoietic cell transplantation using reduced-intensity conditioning.
Ringdén O; Brazauskas R; Wang Z; Ahmed I; Atsuta Y; Buchbinder D; Burns LJ; Cahn JY; Duncan C; Hale GA; Halter J; Hayashi RJ; Hsu JW; Jacobsohn DA; Kamble RT; Kamani NR; Kasow KA; Khera N; Lazarus HM; Loren AW; Marks DI; Myers KC; Ramanathan M; Saber W; Savani BN; Schouten HC; Socie G; Sorror ML; Steinberg A; Popat U; Wingard JR; Mattsson J; Majhail NS
Biol Blood Marrow Transplant; 2014 Nov; 20(11):1777-84. PubMed ID: 25042734
[TBL] [Abstract][Full Text] [Related]
19. Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic Syndrome.
Nakamura R; Saber W; Martens MJ; Ramirez A; Scott B; Oran B; Leifer E; Tamari R; Mishra A; Maziarz RT; McGuirk J; Westervelt P; Vasu S; Patnaik M; Kamble R; Forman SJ; Sekeres MA; Appelbaum F; Mendizabal A; Logan B; Horowitz M; Cutler C
J Clin Oncol; 2021 Oct; 39(30):3328-3339. PubMed ID: 34106753
[TBL] [Abstract][Full Text] [Related]
20. Ofatumumab as part of reduced intensity conditioning in high risk B-cell lymphoma patients: final long-term analysis from a prospective multicenter Phase-II Trial.
Cabrero M; López-Corral L; Jarque I; de la Cruz-Vicente F; Pérez-López E; Valcárcel D; Sanz J; Espigado I; Ortí G; Martín-Calvo C; de la Serna J; Caballero D;
Bone Marrow Transplant; 2024 Mar; 59(3):359-365. PubMed ID: 38167647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
